187 related articles for article (PubMed ID: 11401781)
1. Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignangies.
Maio M; Altomonte M; Calabro L; Fonsatti E
Front Biosci; 2001 Jun; 6():D776-84. PubMed ID: 11401781
[TBL] [Abstract][Full Text] [Related]
2. General aspects of anti-angiogenesis and cancer therapy.
Zogakis TG; Libutti SK
Expert Opin Biol Ther; 2001 Mar; 1(2):253-75. PubMed ID: 11727534
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic treatment strategies for malignant brain tumors.
Kirsch M; Schackert G; Black PM
J Neurooncol; 2000; 50(1-2):149-63. PubMed ID: 11245274
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics.
Zhu Z; Bohlen P; Witte L
Curr Cancer Drug Targets; 2002 Jun; 2(2):135-56. PubMed ID: 12188915
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic angiogenesis inhibitors in the treatment of cancer.
Hidalgo M; Pierson AS; Holden SN; Bergen M; Eckhardt SG
Adv Intern Med; 2001; 47():159-90. PubMed ID: 11795074
[No Abstract] [Full Text] [Related]
6. Anticancer therapy with angiogenesis inhibitors.
Ghilardi C; Bani MR; Giavazzi R
Tumori; 2001; 87(6):S14-6. PubMed ID: 11989610
[No Abstract] [Full Text] [Related]
7. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.
Schlaeppi JM; Wood JM
Cancer Metastasis Rev; 1999; 18(4):473-81. PubMed ID: 10855790
[TBL] [Abstract][Full Text] [Related]
8. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis inhibition in solid tumors.
Rosen LS
Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
11. Endothelial survival factors as targets for antineoplastic therapy.
Reinmuth N; Stoeltzing O; Liu W; Ahmad SA; Jung YD; Fan F; Parikh A; Ellis LM
Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.
Sledge GW
Semin Oncol; 2002 Jun; 29(3 Suppl 11):104-10. PubMed ID: 12138404
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.
Stefanik DF; Fellows WK; Rizkalla LR; Rizkalla WM; Stefanik PP; Deleo AB; Welch WC
J Neurooncol; 2001 Nov; 55(2):91-100. PubMed ID: 11817706
[TBL] [Abstract][Full Text] [Related]
14. VEGF receptor signaling in tumor angiogenesis.
McMahon G
Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
[TBL] [Abstract][Full Text] [Related]
15. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules.
Kay NE; Bone ND; Tschumper RC; Howell KH; Geyer SM; Dewald GW; Hanson CA; Jelinek DF
Leukemia; 2002 May; 16(5):911-9. PubMed ID: 11986954
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
[TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines.
Gottstein C; Wels W; Ober B; Thorpe PE
Biotechniques; 2001 Jan; 30(1):190-4, 196, 198 passim. PubMed ID: 11196310
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenesis -- therapeutic strategies and clinical implications for brain tumors.
Puduvalli VK; Sawaya R
J Neurooncol; 2000; 50(1-2):189-200. PubMed ID: 11245279
[TBL] [Abstract][Full Text] [Related]
19. Targeting of vasculature in cancer and other angiogenic diseases.
Kumar S; Li C
Trends Immunol; 2001 Mar; 22(3):129. PubMed ID: 11334027
[No Abstract] [Full Text] [Related]
20. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.
Fonsatti E; Altomonte M; Nicotra MR; Natali PG; Maio M
Oncogene; 2003 Sep; 22(42):6557-63. PubMed ID: 14528280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
